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Edited by Miguel De la RosaAbstract A novel methodology to predict the local conforma-
tional changes in a protein as a consequence of missense muta-
tions is proposed. A pentapeptide at the locus of mutation plays
the dominant role and it is analyzed in terms of tripeptides. A
measure for spatial and temporal ﬂuctuations in a pentapeptide
is devised and validated. The method does not involve any prior
knowledge of structural templates from sequence homology
studies. Structural deformations can be predicted with about
70–80% reliability in any protein. Disease causing mutations
and benign mutations have been addressed. In particular, p53, ret-
inoblastoma protein and lipoprotein lipase are studied in detail.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Inherited diﬀerences in DNA sequence contribute to pheno-
typic variation, inﬂuencing an individual’s anthropometric
characteristics, disease susceptibility and response to the envi-
ronment [1]. About 90% of sequence variants in humans are
due to diﬀerences in single bases of DNA called single nucleo-
tide polymorphisms (SNPs) [2]. SNPs are DNA allelic variants,
which arise out of single nucleotide substitutions and have an
appreciable allele frequency in a population [3]. Non-synony-
mous SNPs in the coding regions of genes (nsSNPs) or in reg-
ulatory regions are more likely to cause functional diﬀerences
than SNPs elsewhere [4]. The availability of SNP data in public
databases like dbSNP and locus centric mutation databases
has made a systematic analysis of SNP data possible. nsSNPs,
which occur near functionally important sites of a protein, are
most likely to cause structural deformation of the protein lead-
ing to disease. However, not all nsSNPs are associated with
disease. In instances where a mutation is found at an impor-
tant site of a protein and yet does not result in a disease phe-
notype, it is realized that there are alternate mechanisms/
proteins [5] in the organism masking the deleterious eﬀect of
the mutation. To understand the relationship between genetic
and phenotypic variation, it is essential to assess the structural
consequences of the nsSNPs in proteins.*Corresponding authors. Fax: 91 44 22541586.
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doi:10.1016/j.febslet.2006.02.079Several studies have addressed the eﬀect of nsSNPs on pro-
tein structure and function by mapping missense mutations to
three dimensional structures and homology models. There are
numerous reports of site directed mutagenesis experiments in
the literature, which shed light on the structural and possible
functional consequences of non-synonymous cSNPs. In one
comprehensive structure based study, known disease muta-
tions were mapped onto three dimensional structures of pro-
teins in order to qualify how a disease phenotype can be
explained by a destructive eﬀect on protein structure or func-
tion [6]. 70% of the disease causing mutations mapped to struc-
turally and functionally important sites of proteins. In another
study [7], the structural features of a number of non-synony-
mous cSNPs were studied and a model for assigning a mecha-
nism of action of each mutation in the protein was developed.
Allelic variants were classiﬁed as neutral or deleterious. The
variants were further classiﬁed as aﬀecting protein stability,
binding, catalysis, allosteric response and post translational
modiﬁcations. Most of the structure related studies rely on
the availability of 3D structures or templates for homology
based predictions. Typically proteins, which are atleast 40%
homologous to the one being modeled, are used as structural
templates. This is a severe restriction to model builders in
understanding observed mutations. Structural neighbourhood
models and phylogenetic information was also used to derive
features, which can serve as indicators of nsSNPs eﬀect on
function [8]. Purely sequence based approaches have also been
employed in assessing the eﬀect of nsSNPs. One such approach
SIFT uses sequence homology to predict whether an amino
acid substitution will aﬀect protein stability and function and
hence potentially alter the phenotype [9,10]. The relative
strengths and complementarity of the evolutionary and struc-
tural models was also investigated [11]. The performance of
classiﬁers was characterized as a function of the number of
homologs available for the calculation of evolutionary fea-
tures. It was observed that when fewer homologous sequences
were available, structural information substantially improved
the prediction accuracy of deleterious mutations. With the ad-
vent of the genomic era, understanding mutations at an auto-
mated pace has become a necessity [12].
When a protein undergoes a single amino acid change, it is
expected that its shape will be deformed at the same locus.
However this small perturbation does aﬀect the neighbouring
residues as well. The overall shape of the protein may remain
unchanged, but a short stretch of about 10 residues may under-
go a small deformation. In vivo, when the protein interacts
with other molecules the local ﬂuctuations of the conformation
can also dominate the interaction. Therefore a mutation canblished by Elsevier B.V. All rights reserved.
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In this study we attempt to predict the deformation and ﬂuctu-
ation (temporal deformation) of the conformation from the
knowledge of short peptides in a protein such as tripeptides.
Tripeptide is the smallest unit, which captures the bending of
the main chain of a protein. By concatenating overlapping
tripeptides we can build the entire protein chain. At the locus
of mutation, three tripeptides are aﬀected. Consequently, if
any of the three disturb the wild type behaviour, structural
and temporal deformations can be seen. This picture shows
that in any protein, a pentapeptide unit, which has three diﬀer-
ent tripeptides, plays the dominant role, which we purport to
understand.
A tripeptide for example ‘‘ANR’’ might occur in various
proteins and each of these creates a diﬀerent local molecular
environment, consequently it takes various conformations.
We analyze these shapes statistically to infer mean and stan-
dard deviations (S.D.) in various neighbour distances. These
S.D. can be taken as a measure of ﬂuctuations of the tripeptide
‘‘ANR’’ in vivo. Tripeptide data analyzed from the PDB data-
bank show that corresponding mean distances between various
Ca and Cb atoms are about the same across all tripeptides
making them indistinguishable. The S.D.s in various distances
however, are varied across tripeptides implying that each of
these ﬂuctuates diﬀerently. Indeed about 18% of tripeptides
have very little (<0.4 A˚), while 4% have large (>0.7 A˚) ﬂuctu-
ations [13]. We ﬁnd that typically, a mutation aﬀects the ﬂuc-
tuating properties of the local pentapeptide, which in turn
causes a local conformation change along the peptide chain.
We deﬁne a measure, which captures ﬂuctuations of pentapep-
tides. We validate this measure against crystallographic vari-
ants, disease causing SNPs, non-disease causing or benign
SNPs, and short functional motifs. Our prediction of the ef-
fects of disease causing and the benign SNPset was also cross
validated with the results of homology modeling based studies
[7]. We apply our strategy for the prediction of eﬀects of dis-
ease causing mutations of certain key proteins like p53 [14],
retinoblastoma protein (RB1) [15] and lipoprotein lipase [16].C
Cβ
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In an earlier study, we had analyzed 0.27 million tripeptides from
1220 good resolution protein structures from the PDB [13]. Inter-
atomic distances between the Ca and Cb atoms of each of these tripep-
tides was computed (Fig. 1) and the results were statistically analyzed.
The distances between residues 1 and 2 and residues 2 and 3 of a tri-
peptide, respectively, were termed as nearest neighbour distances and
the distances between residues 1 and 3 of a tripeptide were called as
next to nearest neighbour distances. The tripeptide knowledge base
consists of statistics of all distances between nearest neighbour and
next to nearest neighbour positions of Ca and Cb atoms. The tripep-O
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Fig. 1. Tripeptide distances representation of a tripeptide. The dotted
lines show the next to nearest neighbour distances (aa, ab, ba, bb).tides in this knowledge base can be considered as sequence structure
correlates. This data set typically has about 0.2 A˚ S.D. in the co-ordi-
nate positions of any atom. It was found that the nearest neighbour Ca
and Cb atomic distances have S.D.s ranging from 0 to 0.4 A˚ suggesting
that they are all within allowed (experimental) S.D.s. However, in or-
der to capture the local bending information we need at least one next
to nearest neighbour distance data. There are four next to nearest
neighbour mean distances which have a S.D. ranging typically between
0.4 and 0.7 A˚. Next to nearest neighbour mean distances when com-
pared across all tripeptides show that they are all within allowed
S.D.s. A measure of the ﬂuctuating characteristic of a tripeptide can
be understood after we present how this data can be used to construct
the three dimensional structure of a protein. We begin with a solid
structure in three dimensions given by mutual distances between Ca1,
Cb1, Ca2, Cb2 points of the ﬁrst two residues. To ﬁx Ca3 we need three
distances from the previous points. Noting that the nearest neighbour
distances have the standard deviations in the range 0–0.4 A˚ and are the
least ﬂuctuating, these have to be Ca2 Ca3, Cb2 Ca3 (nearest neighbour
distances), the third can be either Ca1 Ca3 or Cb1 Ca3, whichever has
lower S.D. Then to determine Cb3 we need to use only Ca2 Cb3, Cb2
Cb3, Ca3 Cb3. Alternatively, we may ﬁx Cb3 ﬁrst and Ca3 subsequently,
in which case the other two nearest neighbour distances become rele-
vant. This procedure can be iterated to ﬁx the co-ordinates down the
polypeptide chain. Hence, for any particular tripeptide we need only
one next to nearest neighbour distance of the four possible next to
nearest neighbour distances aa, ab, ba, bb from the data. We pick
the one with the lowest S.D. amongst the next to nearest neighbour
distances (1,3 distances) and call it the characteristic of the tripeptide.
In mutation analysis we use this characteristic of the tripeptide as a
measure of ﬂuctuations. We compare the ﬂuctuating characteristic of
two diﬀerent tripeptides. If the ﬁrst tripeptide has the lowest S.D. in
ab (r1ab) while the second has in aa (r2aa), we look at the ratios
R1 = (r1ab)/(r2ab) and R2 = (r2aa)/(r1aa). If either R1 or R2 is outside
the range of 0.8–1.2, i.e., 20% deviation, we conclude that the tripep-
tides ﬂuctuate diﬀerently.
In a missense mutation, we compare the corresponding tripeptides of
the wild type and mutant at the locus of the aﬀected pentapeptide as
described above. After computing the six ratios: three for the wild type
tripeptides going into the corresponding mutant tripeptides and vice
versa, we deﬁne the largest deviant of these from unity as R. If R is
within the range 0.8–1.2, we conclude that the ﬂuctuations of the wild
type and mutant pentapeptides are similar otherwise they are dissimi-
lar. R is the measure of ﬂuctuations due to the mutation. This is illus-
trated with an example: a disease causing SNP resulting in R273Q in
p53, the wild type pentapeptide at the site of the mutation is EVRVC;
and the mutant EVQVC (Fig. 2). The three tripeptide pairs to be com-
pared are (EVR, EVQ); (VRV, VQV); (RVC, QVC). The correspond-
ing standard deviations of the next to nearest neighbour residue
distances of these tripeptides are obtained from the tripeptide knowl-
edge base [http://www.au-kbc.org/research_areas/bio/projects/protein/
tri.html] and the characteristic of each tripeptide is determined. The
six ratios are computed. The largest ﬂuctuation R was found to be
in the last pair, namely in RVC, the characteristic S.D. is r aaCβ
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Fig. 2. Missense mutation ‘‘R273Q’’ in p53 protein. The wild type
(‘‘EVRVC’’) and the mutant (‘‘EVQVC’’) pentapeptides are shown.
The ﬁrst number in each pair corresponds to wild type’s S.D. or the
characteristic if enclosed in [ ] and the second to that of the mutant.
S. Anishetty et al. / FEBS Letters 580 (2006) 2071–2080 2073[0.53], while r aa for QVC is 0.5; the characteristic S.D. of QVC is rba
[0.32] while r ba of RVC is 0.81. The most deviant ratio for this pair is
0.32/0.81 = 0.39 = R.3. Datasets
Four diﬀerent datasets were used in this study; crystallo-
graphic variants, functional motifs, disease causing SNPs
and non-disease causing or benign SNPs. For the crystallo-
graphic data involving site-directed mutagenesis experiments
a keyword search of Protein Data Bank [17] was used to iden-
tify PDB entries, which are single residue variants. The PDB
entries were then retrieved from the Protein Data Bank. The
corresponding primary citation for the PDB entry was re-
trieved from PubMed literature database and the experimental
analysis of the eﬀect of the mutation recorded. Disease causing
and benign missense mutation data was retrieved from Swiss-
Prot [18] and dbSNP [19] database. A subset of this data cor-
responds to the disease and the non-disease set used in
homology model assisted mutation studies [7]. Locus speciﬁc
mutation databases IARC p53 database Release 8.0 [14],
RB1 gene mutation database [15] were used to retrieve the mis-
sense mutations in the case of p53 and retinoblastoma proteins
respectively. Since, a mutation may be recorded more than
once in the p53 database, only distinct mutations were ex-
tracted as a dataset for further analysis.
In the case of functional motifs a slightly diﬀerent strategy
was adopted. Motifs are short conserved subsequences presentTable 1
Co-relation with crystallographic variants header line shows the PDB ID alo
PDB ID: 1kb3 human pancreatic a amylase
R195A+/ 1.12 R195Q/ 1.25 N298S/
PDB ID: 1dlr/1dlt human dihydrofolate reductase
L22Y+/+ 1.20 L22F/+ 0.63 L22W/+ 2
PDB ID: 133l/134l human lysozyme
R115H+/+ 0.95 R115E/ 0.45
PDB ID: 1h4a human c-D crystallin
R36S/ 1.40 R58H/ 0.65
PDB ID: 1egd/1ege human medium chain acyl-coA dehydrogenase
T255E/ 1.62 E376G/ 1.40
PDB ID: 1b5z human lysozyme
S82A/ 0.56
PDB ID: 1f8u human acetylcholinesterase complex
E202Q+/+ 0.82
PDB ID: 1n5o breast cancer type 1 susceptibility protein Brct domain 1646–1
M1775R/ 1.41
PDB ID: 1t2u breast cancer type 1 susceptibility protein Brct domain 1646–1
V1809F/ 0.74
PDB ID: 1fkc human prion protein (Mutant E200K) fragment 90–231
E200K/+ 2.08
PDB ID: 1hik human interleukin-4
R88Q/ 0.48
Each entry represents the mutation in the crystallographic variant followed by
ﬁrst ‘‘+’’ or ‘‘’’ corresponds to the tripeptide based prediction, and the secon
the most deviant ratio R.within all members of a protein family. These motifs arise be-
cause of particular requirements in the structure of speciﬁc re-
gion(s) of a protein, which may be important for example for
their binding properties or enzymatic activity. Since they are
all functionally identical, it may be assumed that the local
structure adopted by these regions speciﬁed by the motifs is
essentially the same. The changes in the actual subsequence
of the motif in diﬀerent members of the family can be likened
to benign variations leading to similar local structures.
Short functional motifs with lengths ranging from 4 to 10
were retrieved from the Prosite [20] motif database. The exact
peptide sequences (as seen across species including Homo
sapiens) that conform to each of these motifs were also re-
trieved from the multiple sequence alignment given alongside
the Prosite entry. The peptide, which occurs the maximum
number of times, is taken as equivalent to wild type and
the others as benign variants. Note that, depending on the
length of the motif and the number of positions that the pep-
tides diﬀer from the wild type, the number of pairs of tripep-
tides evaluated and cross ratios computed in the case of each
motif diﬀers. 0.6–1.4 is set as the allowed range of ﬂuctua-
tions for those variants, which diﬀer at more than one posi-
tion from the wild type peptide.4. Results
The format used for presenting the eﬀect of a mutation is ex-
plained with an example entry R58H/ 0.65. This notationng with the protein name
1.68 R337A/ 0.63 R337Q/ 0.65
.22 L22R/ 1.40
859
859
the symbol ‘‘+’’ (no structural change) or ‘‘’’ (structural change). The
d ‘‘+’’ or ‘‘’’ corresponds to the literature report. This is followed by
2074 S. Anishetty et al. / FEBS Letters 580 (2006) 2071–2080depicts that Arg at position 58 mutates to His; this is followed
by a symbol ‘‘+’’, denoting that it is within the ﬂuctuating
range and therefore structurally similar to the wild type or a
‘‘’’ denoting that it has caused a deformation signiﬁcantly
diﬀerent from the wild type. Similarly the second ‘‘+’’ or
‘‘’’ denotes whether a change has occurred or not, according
to another study such as homology modeling or crystallo-
graphic variant studies. Note that for functional motifs, the
second symbol is always a ‘‘+’’ as they are all benign variants.
The number that follows the symbols denotes the most deviant
tripeptide S.D. ratio R as explained in Section 2. The results
obtained in various datasets are discussed below.5. Crystallographic variants
Many mutant protein crystallographic structures (crystallo-
graphic variants) have been analyzed in the literature. We ana-
lyzed 21 mutations across 14 crystal structures. Our analysis
agrees with 17 out of the 21 giving a prediction accuracy of
81%. The results of these variants are presented in Table 1.
We discuss the results of two key proteins BRCA1 and
cDCrystallin in detail.
Many forms of genetic cataracts are associated with muta-
tions in the Arginine residues of the cDcrystallin protein.
Two forms of genetic cataracts are caused by mutations in
cDcrystallin gene: the aculeiform cataract associated with theTable 2
Functional motifs
Motif Id: PS00014 WT: HDEL ln = 4 ER_target sequence signature
KDEL+/+ 1.07 HNEL/+ 0.49
RDEL+/+ 1.0 KEEL/+ 0.59
ADEL+/+ 1.28 KQEL+/+ 0.66
Motif Id: PS00032 WT: IYPWMR ln = 6 homeobox antennapedia-type pro
LYPWMR+/+ 1.20 EYPWMK/+ 1.43
VYPWMR+/+ 1.22 IFPWMK+/+ 0.97
IFPWMR+/+ 0.97 LFPWMR+/+ 1.0
Motif Id: PS00161 WT: KKCGHM ln = 6 isocitrate lyase signature
KKCGHL+/+ 0.92 KKCGHQ+/+ 1.13
Motif Id: PS00199 WT: CTHLGCV ln = 7 Rieske iron-sulfur protein signat
CKHLGCT+/+ 1.14 CTHLGCI+/+ 0.92
CTHLGCS+/+ 1.13
Motif Id: PS00064 WT: LGEHGDS ln = 7 L-lactate dehydrogenase active it
LGEHGNS/+ 0.50 MGEHGDS+/+ 0.94
IGEHGDS/+ 1.29 VGEHGDS+/+ 0.98
Motif Id: PS00120 WT: VHLLGYSLGA ln = 10 lipases, serine active site
IWVTGHSLGG/+ 0.69 LAISGHSRGG+/+ 0.71
VFLIGHSVGC/+ 1.53 VFLIGHSLGC/+ 1.53
VQLIGHSLGA+/+ 0.72 VHLIGHSLGA+/+ 0.75
VLVSGHSLGG+/+ 1.34 VVVSGHSLGG+/+ 0.76
LHYVGHSQGT/+ 0.59 IHYVGHSQGT/+ 0.59
IHVIGHSLGA+/+ 0.75 VHLIGHSLGS+/+ 0.75
VNLIGHSQGA+/+ 1.34 VNLIGHSQGG+/+ 1.34
VHLVGHSMGG+/+ 0.70 IHLVGHSMGG+/+ 0.70
LVVVGHSLGA+/+ 0.83 IRLVGHSLGA+/+ 0.72
IAIIGHSFGG+/+ 0.60 IAVIGHSFGG+/+ 0.60
IVLVGHSMGC/+ 0.45 IVVTGHSLGA+/+ 1.29
VNVIGVSWGG+/+ 1.38
The header line of each motif has the Prosite Motif ID, the most frequent pep
Each entry has the benign variants with the positions at which they diﬀer fro
‘‘’’ (structural change) corresponds to the tripeptide based prediction. TheR58H mutation [21] and the crystal cataract associated with
the R36S mutation [22]. Arginine residues play an important
role in maintaining the solubility of c Dcrystallins. Both these
mutant proteins have lower solubility and crystallize more
readily than the wild type, leading to lens opacity due to the
formation of crystal structures. The R58H mutant protein
loses the direct ion–pair interaction present in the wild type
[23]. In our study, we ﬁnd that both these mutations cause al-
tered local structural conformation as is apparent from our
most deviant ratio being 1.40 for R36S (R36S/ 1.40) and
0.65 for R58H (R58H/ 0.65).
Another interesting case study is presented in the mutant
studies of BRCA1 protein. BRCA1 is one of the breast cancer
susceptibility genes involved in DNA repair and tumor sup-
pression [24]. The carboxy terminal BRCT repeats in BRCA1
protein is essential for its tumor suppressor activity. A well
characterized cancer associated mutation M1775R in the
BRCT tandem repeat domain of BRCA1 is shown to cause
charge–charge repulsion, rearrangement of the hydrophobic
core and disruption of hydrogen bonding network at the inter-
face between the two BRCT repeats leading to a conforma-
tionally unstable mutant [25]. Our analysis indicates a local
structural deformation for this mutant: M1775R/ 1.41.
The BRCT repeats interact with phosphorylated protein tar-
gets containing the sequence ‘‘pSer-X-X-Phe’’. The diminished
peptide binding capacity observed for cancer associated
BRCA1–BRCT variants provide an explanation for increasedREEL/+ 0.59 RNEL+/+ 1.30
HEEL/+ 0.59 KNEL+/+ 1.30
QDEL+/+ 1.11
tein signature
FYPWMA+/+ 1.19 MYPWMR+/+ 1.19
VYPWMK+/+ 1.22 EFPWMK+/+ 0.93
MFPWMR/+ 0.52 VYPWMT+/+ 1.22
KRCGHL+/+ 0.64 KRCGHR+/+ 0.64
ure1
CTHLGCT+/+ 0.96 CTHLGCL+/+ 1.17
e.
IGEHGDT/+ 0.50 AGEHGDS+/+ 0.67
LGEHGDT/+ 0.50 MGEHGDT/+ 0.50
VAVMGHSRGG+/+ 0.72 LTVTGHSLGA+/+ 1.29
VYYVGHSQGT/+ 0.56 IYYVGHSQGC+/+ 1.34
VHVIGHSLGA+/+ 0.75 VQYVGHSQGT/+ 0.54
VHFLGHSLGA+/+ 1.30 VHLIGYSLGA+/+ 0.81
VHIIGHSLGS+/+ 0.75 VHVIGHSLGS+/+ 0.75
VNLVGHSQGG+/+ 1.34 VNLIGHSHGG/+ 2.44
VAVTGHSLGG/+ 1.54 VIVTGHSLGG+/+ 1.29
VHFIGHSMGG+/+ 1.30 VVFTGHSLGG+/+ 1.29
IRLIGHSLGA+/+ 0.72 VAVMGHSFGG+/+ 0.60
IAVMGHSFGG+/+ 0.60 VNVIGVSWGG+/+ 1.38
VCIVGHSMGG+/+ 0.70 IALMGHSFGG+/+ 0.60
tide Wild type, length of the motif, and a short description of the motif.
m the wild type shown in bold. The ﬁrst ‘‘+’’ (no structural change) or
second symbol is always a ‘‘+’’.
Table 3
Disease causing mutations
Gene: ARSA arylsulfatase A precursor
G32S+/ 0.91 L68P/ 0.59 P82L/ 0.54 R84W/ 1.26 G86D/ 0.22 P94A/ 0.66
S95N/ 0.55 S96F/ 0.52 G99D/ 1.32 G99V/ 1.27 G122S/ 0.62 L135P/ 0.52
P136L/ 0.7 P148L/+ 1.65 D152Y/ 1.6 G154D/ 2.18 P155R/+ 1.82 P167R/+ 1.60
D169N/ 1.21 C172Y+/ 1.11 I179S/ 0.48 Q190H/ 1.47 P191T+/ 1.14 Y201C/ 2.02
A212V/ 0.64 A224V/ 1.44 H227Y/ 1.53 P231T/ 0.58 R244H/+ 1.36 R244C/ 1.32
G245R/ 1.9 D255H/ 1.54 T274M/ 0.48 S295Y/ 2.58 L298S/+ 0.62 C300F/ 1.41
R311Q+/ 1.17 A314T/ 0.59 T327I/+ 0.55 D335V/ 0.61 N350S/ 1.35 K367N/ 1.28
R370Q/ 0.43 R370W/ 2.8 P377L/ 0.61 E382K/ 1.32 R384C/ 0.69 R390Q/ 1.23
R390W/ 1.51 T391S/ 0.56 H397Y/ 0.47 T409I/+ 0.53 P425T/ 0.27 P426L/ 1.81
L428P/ 1.79 A464V/ 1.93
Gene: SOD1 superoxide dismutase [Cu–Zn]
A4V/ 0.74 A4T/ 2.23 V7E/ 1.43 L8Q/ 0.35 G12A/ 1.48 V14M/ 1.55
G16S/ 0.52 E21G/ 0.4 E21K/ 0.59 G37R/ 1.93 L38V/ 1.23 G41D/ 1.52
G41S/ 0.65 H43R+/ 0.86 H46R/ 1.4 H48Q/ 1.37 G72S/ 0.36 L84F/ 1.31
L84V/ 2.38 G85R/ 1.24 N86S/+ 1.35 D90A/+ 1.22 G93D/ 0.5 G93S/ 0.49
G93R/ 0.65 E100K/ 1.48 D101G/ 1.25 D101N/ 1.25 I104F+/ 1.19 L106V+/ 1.13
G108V+/ 0.9 I112T+/ 0.83 I113T+/ 0.85 D124V/ 0.5 D125H/ 0.75 S134N/ 1.51
N139K/ 0.66 L144S/ 0.62 L144F/ 0.54 A145T/ 0.64 C146R/ 1.87 V148G/ 1.35
V148I+/ 1.12 I149T/ 1.31 I151T/ 0.44
Gene: GUSB b-glucuronidase
C38G/ 2.66 S52F/ 1.33 G136R+/ 1.2 P148S/+ 1.34 E150K/ 0.73 D152N+/ 1.2
L176F/ 0.74 R216W/ 0.84 Y320S/ 0.86 Y320C/ 0.53 H351Y/ 0.71 A354V/+ 1.24
R374C/ 0.43 R382H/ 1.25 R382C+/ 1.14 P408S/ 2.45 P415L/+ 1.69 R435P/ 1.49
R477P/ 1.84 Y495C/ 1.81 Y508C+/ 0.96 G572D/ 1.34 K606N/ 1.93 R611W/ 2.08
A619V/ 0.68 Y626H+/ 0.9 W627C/ 2.04
Gene: ALDH10 aldehyde dehydrogenase
I45F+/ 1.09 V64D/ 1.69 L106R/ 0.67 P114L/ 0.58 P121L/ 0.67 T184M/ 0.51
T184R/ 0.51 G185A/ 0.79 C214Y/ 0.29 C226W+/ 1.16 C237Y/ 1.9 D245N/2.22
Y279N/ 0.67 M328I/3.17 S365L/+ 0.47 N386S/ 1.21 G406R+/ 1.09 H411Y/ 1.35
S415N/ 0.45 F419S/ 1.33 R423H/2.1 K447E/ 1.34
Gene: ACADM acyl-CoA dehydrogenase
R28C/ 0.41 Y42H/ 0.65 I53T/ 0.61 C91Y/ 1.29 T96I-/1.63 G112R/ 0.59
M124I/+ 1.65 T168A/ 0.28 G170R/ 1.37 R181L/ 1.54 C219R/ 0.68 S220L/ 0.74
R256T+/ 1.13 M301T/ 1.61 K304E/ 0.66 S311R/ 0.48 Y327T/ 0.59 Y327C/ 1.39
I350T/+ 0.7
Gene: FGG ﬁbrinogen
G268E/ 1.68 R275H/ 2.67 R275C/ 0.52 N308I+/ 1.11 N308K+/ 1.09 G309D/ 1.82
M310T+/ 0.96 Q329R/3.96 D330Y/ 5.16 D330V/3.76 N337K/ 1.21 S358C/ 1.84
D364H/ 1.51 K380N/ 0.55 M384V/ 0.72
Gene: GNAS1 guanine nucleotide-binding protein G(s), a-subunit
L99P/ 1.74 P115S/ 0.45 P115L/ 0.54 R165C/ 1.45 R201S/ 0.41 R201L/ 1.81
R201H/ 0.41 R201C/ 4.12 Q227H/ 1.46 Q227R/ 1.43 R231H/ 0.7 S250R/ 1.50
R258W/ 0.61 E259C+/ 0.96 A366S/ 0.58 R385H/+ 0.33
Gene: ARSB arylsulfatase B
T92M/ 1.20 R95Q/ 1.29 C117R/ 0.56 G137V/ 1.51 G144R/ 2.70 R160Q/ 0.70
C192R/ 1.27 Y210C/ 0.79 L236P/ 0.72 L321P/ 0.37 V358M/ 1.80 H393P/ 0.49
C405Y/ 0.56 L498P/ 1.74 C521Y/ 1.68
Gene: F13A1 coagulation factor XIII A chain
N60K/ 1.31 M242T/ 0.33 R252I/ 1.4 R260H+/ 1.18 R326Q/ 0.32 A394V/ 0.62
R408Q/ 0.59 V414F/ 0.73 L498P/ 1.29 N541K/ 2.36 G562R/ 1.38 L660P/ 0.49
L667P/ 1.45
Gene: ACADS acyl-CoA dehydrogenase
R46W/+ 0.69 G90S+/ 1.06 G92C/+ 0.28 R107C/ 1.75 R171W/+ 1.43 W177R/+ 0.75
A192V/ 0.61 G209S/ 1.69 R352W/ 1.98 S353L/ 1.63 R380W/ 0.76 R383C/ 0.41
Gene: PPGB protective protein for galactosidases
Q21R/ 0.78 S23Y/ 1.46 W37R+/ 1.1 S62L/ 1.25 V104M+/ 0.80 L208P/ 0.61
Y221N/+ 0.55 Y367C/ 1.41 M378T/ 0.58 G411S/ 0.76 F412V/ 0.73
Gene: IVD isovaleryl-CoA dehydrogenase
L13P/+ 1.62 R21P/ 1.57 D40N/ 1.59 G170V/ 1.25 A282V/+ 0.68 C328R/ 2.86
V342A/ 0.62 R363C/ 0.48 R382L/ 1.49
(continued on next page)
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Table 3 (continued)
Gene: ALDOB fructose-bisphosphate aldolase B
C134R/ 0.54 W147R/ 0.37 A149P/ 0.46 A174D/ 0.69 L256P/ 1.29 R303W/ 0.72
N334K/ 0.37 A337V/ 1.35
Gene: NP purine nucleoside phosphorylase
S51G/ 1.4 E89K/ 0.39 D128G+/ 1.15 A174P/ 0.60 Y192C/ 0.44 R234P/ 1.59
Gene: CA2 carbonic anhydrase
K17E/ 1.54 Q91P/ 0.56 H106Y/ 0.74 P235H/2.20 N251D/ 1.24
Gene: PCBD pterin-4-alpha-carbinolamine dehydratase
T78I/ 0.55 C81R/+ 2.86 R87Q/ 0.67 E96K/ 0.69
Gene: ETFA electron transfer ﬂavoprotein a-subunit
G116R/ 0.27 V157G+/ 1.18 T171I/+ 1.52 T266M/ 1.43
Gene: LYZ human lysozyme
I56T/ 0.23 D67H/ 1.86
Gene: PYGL glycogen phosphorylase
N339S/ 1.33 N377K/ 2.01
Gene: RBP4 retinol binding protein
I41N/ 0.70 G75D/ 0.73
Gene: ALDOA fructose-bisphosphate aldolase A
D128G/ 1.25 E206K/ 1.29
Gene: TSHB thyroid-stimulating hormone b subunit
C105V/ 1.48
Gene: GNAT1 guanine nucleotide-binding protein G(t), a-1 subunit
G37D/ 1.5
The header line shows the gene name along with the protein name. Each entry represents the mutation followed by the symbol ‘‘+’’ (no structural
change) or ‘‘’’ (structural change). The ﬁrst ‘‘+’’ or ‘‘’’ corresponds to the tripeptide based prediction, and the second ‘‘+’’ or ‘‘’’ when present
corresponds to the homology model based prediction. This is followed by the most deviant ratio R.
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variant V1809F in this instance has also been predicted to be
deleterious by our analysis: V1809F/ 0.74. It shows that
our approach can be used to evaluate the molecular eﬀects
of naturally occurring mutants or site directed mutagenesis
experiments, albeit at a gross level.6. Functional motifs
In the functional motif category, 106 peptides across 11
functional motifs were analyzed. Results show that prediction
accuracy in this category is around 75%. A representative
dataset is presented in Table 2. Functional motifs are short
stretches of subsequences, which are important for the func-
tionality of a protein. These motifs are more like regular
expressions rather than exact peptides when considered
across species. The peptide that occurs with greatest fre-
quency in a particular motif is taken as the wild type peptide.
The other peptide sequences that a particular motif spans
across species can be considered as benign variants of this
wild type peptide. Benign variants in this dataset may diﬀer
from the wild type peptide motif at more than one position
simultaneously. These are comparable to double mutants,
triple mutants and so on. In such cases, the allowed range
of ﬂuctuations is set to 0.6–1.4. We present a motif
‘‘PS00120’’ as a case study.Triacylglycerol lipases [27] are lipolytic enzymes that hydro-
lyze the ester bond of triglycerides. ‘‘PS00120’’ is a Prosite mo-
tif designed around the active site residue Serine of
triacylglycerol lipases. There are 45 occurrences of this motif
across species including H. sapiens. Most of the peptides diﬀer
at more than three positions from the wild type. 36 out of 45
peptides fall within the allowed ﬂuctuating range. Moreover,
a good majority 23 out of 36 are within 0.7–1.3 range. This
goes to illustrate the fact that a well designed motif around a
conserved site of a protein should yield good results with our
approach. However, one should note that as the regular
expression describing the motif gets more lengthy and generic,
the ambiguity of residues at each position increases and hence
the reliability decreases. We therefore suggest that the usage of
our approach to evaluation of motifs be restricted to motifs,
which are less generic and of length below 10.7. Disease causing mutations
A total of 1478 disease causing mutations from 26 proteins
are analyzed. This includes 1147 mutants from p53, 28 from
lipoprotein lipase and 20 from retinoblastoma protein. 1300
mutants in this set have been predicted to cause local structural
changes giving a prediction accuracy of 88%. The fraction of
mutants not showing structural deformation, i.e., the ratio R
in the range 0.8–1.2, is 12%. Since, the bulk of the mutations
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Fig. 3. Ratio R vs. normalized frequency of disease (dash and dot line)
and non-disease sample set (solid line).
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The prediction accuracy remains the same. Further, 228 mu-
tants from 23 proteins in this disease dataset have results fromTable 4
Tripeptide based prediction: disease causing mutations
p53 protein
D7H 1.52 L35F 1.35 L43S 0.60
S94T 1.53 R110C+ 1.20 R110L 1.22
Y126D 0.09 Y126N 6.0 S127F 1.48
N131S 1.24 N131K 1.53 K132M 0.66
C135F 0.51 Q136E 2.91 Q136K 0.32
C141G 1.76 C141F 1.43 C141Y 1.50
L145Q 0.64 V147D 1.28 V147G 0.53
P151T 1.82 P152L 0.44 P152S 1.96
V157D 0.54 V157I 1.28 R158C 0.38
I162S 0.45 I162V 1.21 K164N 0.66
S166L 2.36 H168R 0.24 M169I 1.48
V172A 0.67 V173E 1.27 V173L 1.26
R175L 1.52 R175P 2.52 R175H 0.21
R181L 0.34 C182S 0.61 D184Y 0.61
P190L 1.65 P191T 2.26 Q192R 0.68
L194R 0.25 I195T 2.82 Y205C 1.51
D228E 0.47 T230I 1.78 I232T 2.0
C238Y 3.18 S240I 2.33 S241F 0.17
G245D+ 1.08 M246R 0.47 M246T 1.42
R248L 1.32 R248Q 1.57 R248W 0.41
I254T 0.54 E258D 0.75 E258K+ 0.85
R273Q 0.39 V274F 1.55 C275Y 2.41
P278H 0.44 P278L 0.32 P278S 2.84
R280T+ 1.15 D281A 1.46 D281E 0.72
R282W 3.31 R283C 1.53 R283G 0.49
T284P 1.87 E285K 0.63 E285Q 0.75
E286G 0.63 E286K 0.71 K292I 1.32
A307T 1.42 P309S 0.67 R337C 2.38
Lipoprotein lipase
W113G+ 1.16 W113R 0.29 H163R 0.59
D183N 1.51 P184R 2.0 A185T 0.51
G215E 0.74 I221T 1.31 D231E 0.65
S271T 0.38 D277N 0.6 S278C 1.90
L330P 0.61 A361T 1.57 E437K 1.22
Retinoblastoma protein RB1
E72Q 1.79 E137D+ 0.86 I185T 0.61
R500G+ 1.08 K530R 0.49 H549Y 0.56
V654E 1.54 R661W 2.27 L662P 1.35
N803K 0.72
The mutation, along with the ﬁrst ‘‘+’’(no structural change) or ‘‘’’(structuhomology modeled studies [7]. The agreement with the homol-
ogy studies is 78%. The results for these mutants are presented
in Table 3. It should be noted that the false negatives in this setW53C 0.25 P60S 2.45 P87Q 1.81
R110P 1.71 F113C 0.43 T125M 2.06
P128S 1.52 A129D 0.53 L130R 0.58
K132Q 0.11 M133T 1.27 C135S 0.29
L137Q 1.44 A138P 0.62 K139N 1.43
V143A 1.93 Q144P 1.64 L145P 1.52
S149P 1.76 P151A 1.59 P151S 1.79
P153T 2.0 T155A+ 1.16 R156P 1.61
R158H 0.50 M160I 1.60 A161S 1.31
K164Q 0.50 Q165L+ 0.80 Q165R 1.29
M169T 0.33 T170M 1.74 T170S 1.48
V173M 1.87 R175C 1.70 R175G 4.23
C176F 2.76 C176W 0.28 P177L 0.53
D186Y 1.58 G187S 1.46 A189P 1.75
H193D 1.30 H193R 0.70 L194P 1.54
R213Q 0.20 Y220C 0.51 Y220H 0.54
Y234H 2.56 M237I 0.21 C238F 3.35
C242F 0.60 G245A+ 0.94 G245C 1.51
M246V 0.57 N247I 0.50 R248G 1.62
R249S 2.0 L252P 2.03 I254N 0.55
V272L+ 1.15 R273C 0.12 R273H 0.27
C275W 0.58 C277G 5.13 P278A 3.04
G279E 1.21 R280K 0.71 R280I 1.29
D281G+ 1.17 D281V 0.61 R282L 1.40
R283H 0.72 R283P 1.71 T284A 1.46
E285V+ 1.20 E286A+ 0.80 E286D 1.49
P300R 1.46 P301L 1.93 R306Q 1.25
G169E 1.43 G181S+ 0.87 D183G 1.89
A203T 1.39 D207E 0.53 H210Q 1.40
I232S 0.94 C243S 1.43 R270H 0.39
S286G 0.77 S286R+ 1.15 M328T 0.48
E437V 1.19
R358Q 1.40 K447Q 1.25 M457R 1.48
S567L 0.51 K616E 0.74 A635P 1.40
H673P 0.36 Q685P 0.50 C712R 1.30
ral change) and the most deviant ratio R is shown for each entry.
Table 5
Non-disease causing mutations
Gene: AVP vasopressin-neurophysin 2-copeptin
P82L/+ 0.59 G119V/ 0.63
Gene: GH1 growth hormone
V136I/+ 0.78
Gene: ELAM E-selectin
C130W/ 1.69 S149R/ 1.80 E295K/ 1.22 E421Q/ 1.77 H468Y/ 0.75 L575F+/ 1.08
Gene: ALDR aldehyde reductase
I14F/ 1.9 H41L/+ 1.21 L72V/ 0.52 G203S/ 1.36 T287I/ 1.41
Gene: ICAM1 intercellular adhesion molecule-1
K155N/ 0.56 G241R/ 1.4 V315M/ 1.54 P352L/ 0.58 R397Q/ 1.41 E469K/ 0.62
Gene: COX1/PTGS1 cyclooxygenase 1
R8W/ 0.70 P17L/ 0.70 R53H/ 1.35 R149L/ 0.61 L237M/ 0.59 K359R/2.6
I443V/ 0.60
Gene: COX2/PTGS2 cycloxygenase 2
R228H/ 0.37 P428A/ 0.48 E488G/ 0.50 V511A+/+ 0.80 G587R/ 1.24
Gene: KLK1 kallikrein
R77H/ 1.42 Q145E/+ 1.43 E186K/ 1.53 V193E+/ 1.19
GENE: LEP leptin
I45V/+ 0.71 V94M/2.65 V110M/ 0.48
Gene: PAI2 plasminogen activator inhibitor-2
N120D+/ 0.83 R229H/ 1.6 N404K/+ 1.58 S413C/ 1.96
Gene: ANX3 annexin A3
S19N+/+ 1.19 I219N/ 0.66 P251L/ 1.72 F291S/ 0.49
Gene: APOD apolipoprotein D
F15S+/ 1.18 S115L/2.78 T178K/+ 0.50
Gene: F3 thromboplastin
T36A/ 1.34 I145V/ 0.5 R163W/ 0.70
Gene: CYH chymase
G46R+/+ 1.17 H66R/ 1.61
Gene: CYP11A cytochrome P450 11A1
E314K+/+ 0.86
Gene: GNB3 guanine nucleotide-binding protein b-subunit 3
D76N/ 1.57 G272S/+ 0.60
Gene: ICAM2 intercellular adhesion molecule-2
A37T/ 0.43 R199H/ 0.22
Gene: PLA2 phospholipase A2
D16A/ 0.43 N89T/+ 1.60 N89K/ 1.88
Gene: CNTF ciliary neurotrophic factor
H182R/+ 1.30
Gene: GH2 growth hormone
R90W/ 1.22
Gene: HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase
I638V+/+ 1.19
The header line shows the Gene name along with the protein name. Each entry represents the mutation followed by the symbol ‘‘+’’(no structural
change) or ‘‘’’ (structural change). The ﬁrst ‘‘+’’ or ‘‘’’ corresponds to the tripeptide based prediction, and the second ‘‘+’’ or ‘‘’’ when present
corresponds to the homology model based prediction. This is followed by the most deviant ratio R.
2078 S. Anishetty et al. / FEBS Letters 580 (2006) 2071–2080do not have an overlap with the false negatives of the homol-
ogy modeling studies. The statistical proﬁle of these mutants is
presented in Fig. 3.We discuss three proteins p53, RB1 and lipoprotein lipase in
detail. p53 and RB1 are tumor suppressor proteins. Mutations
in p53 have been linked to many forms of cancer. Mutations in
S. Anishetty et al. / FEBS Letters 580 (2006) 2071–2080 2079both the alleles of RB1 gene lead to the development of retino-
blastoma, a childhood tumor of the eye [15]. Out of the 1147
disease causing mutations from p53 protein, 1002 mutants
were predicted to cause structural deformations, whereas 145
were predicted not to alter the local structure. An overview
of the ﬂuctuating nature of all the p53 mutations is shown in
Fig. 4. Out of the 20 pathological mutations analyzed in
RB1, 19 of them are predicted to change the local structure.
Lipoprotein lipase is a key enzyme in lipid metabolism.
Many diseases including atherosclerosis, coronary heart dis-
ease and chylomicronemia appear to be directly or indirectly
associated with abnormalities in lipoprotein lipase function
[16]. Out of the 28 mutations analyzed in lipoprotein lipase,
we conﬁrm structural deformations in 25 instances. Only the
mutations presented in the corresponding SwissProt entries
of these three proteins are shown in Table 4.8. Non-disease mutations
67 missense mutations from the non-disease category have
been evaluated and results presented in Table 5. Bulk of the
mutations in this set, fall outside of the allowed ﬂuctuating
range as shown in Fig. 3. 13% of the mutants have the ratio
R in the 0.8–1.2 range, while 22% of the mutants fall within
0.75–1.25 ﬂuctuation range. 35 of these have homology
modeled studies. The agreement of our method with the
homology models is 43%. Our methodology shows that in
this dataset, 87% of the mutants do cause local structural
deformations, yet in the system do not manifest in any del-
eterious eﬀects due to reasons detailed in Section 9. It is fur-
ther seen that all the proﬁles in Figs. 3 and 4 are alike
suggesting that structural variations due to mutations are al-
ways the same.9. Discussion
Tripeptide analysis shows single point mutations invariably
cause protein instability. The precise cause such as loss of H-
bonds or salt bridges, backbone strain, change in catalytic
activity or ligand binding cannot be ascertained by our
method. But in each instance, with further inputs into the anal-
ysis, some of them may be inferred. We concentrated on a
methodology to assess whether there is a structural change
or not. The prediction accuracy in various categories is sum-
marized in Table 6. The main advantage of our methodology
being, the analysis does not require prior structural templates
as in homology modeling studies and therefore has more utilityTable 6
Summary of positive conﬁrmations of ratio R against variou
categories
Category Sample
size
Positive conﬁrmation
in %
Crystallographic variants 21 81
Functional motifs 106 75
Disease 1478 88
Non-disease 67 13
Homology models [disease] 228 78
Homology models [non-disease] 35 43sin the post genomic era. The method can be utilized in design-
ing structural analogues for de novo proteins as well.
We have studied disease causing mutations and non-disease
or benign mutations using our methodology. The disease sam-
ple set conﬁrms structural deformations and a statistical proﬁle
of these changes across many proteins is shown in Fig. 3. We
ﬁnd that in the non-disease dataset also there are structural
changes, 43% of the time in agreement with other modeling
studies, yet there are no deleterious eﬀects. Furthermore, the
statistical proﬁle of these changes is about the same as in the
disease set as shown in Fig. 3. The structural changes are per-
haps irrelevant in these cases, because the locus of mutation is
at a functionally redundant domain or there are overlapping
protein functions [5], alternative pathways or the protein itself
is not crucial to the organism. The issue of disease vs. non-dis-
ease mutation is a multi-parameter decision. Our methodology
can only ascertain the structural aspects, there should be other
corroborative knowledge on the particular domain of the pro-
tein, to conclude about the deleterious eﬀects of the mutation.10. Conclusions
Local pentapeptide structure is important to understand the
conformation and ﬂuctuations of a protein, which in turn dic-
tates the protein stability. This aspect can be successfully
understood in terms of tripeptides. Disease and non-disease
causing mutations are indistinguishable from the structural
deformation statistics alone. Functional motifs are normally
categorized based on sequence homology alone, we suggest
that structural similarity can also be imposed for further
reﬁnement.
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